Cystic Fibrosis (CF) Therapeutics Market Report 2026

The cystic fibrosis (cf) therapeutics market size has grown strongly in recent years. It will grow from $8.34 billion in 2025 to $8.91 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high prevalence of cystic fibrosis, limited early diagnostic tools, reliance on conventional mucolytic therapies, gradual adoption of cftr modulators, regional healthcare infrastructure variability.

The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.72 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to advancements in gene therapy, increased adoption of digital health solutions, rise in precision medicine applications, expansion of pediatric cf treatment programs, growing investment in rare disease therapeutics. Major trends in the forecast period include personalized cystic fibrosis therapies, advanced pulmonary drug delivery systems, gene editing & cftr gene therapy research, patient adherence & remote monitoring solutions, orphan drug development for rare cf mutations.

The increasing number of patients suffering from cystic fibrosis is expected to propel the growth of the cystic fibrosis (CF) therapeutics market going forward. Cystic fibrosis is a hereditary disorder that causes severe damage to the lungs, digestive system, and other organs. CF therapeutics are used to manage the condition by thinning thick mucus in the lungs, making it easier to clear through coughing and improving respiratory function. As the patient population grows, the demand for effective treatment options continues to rise, supporting market expansion. For instance, in 2023, according to the Cystic Fibrosis Foundation, a U.S.-based nonprofit organization, there were 33,288 individuals recorded in the CF Patient Registry in 2023, compared to 32,547 individuals in 2022, reflecting a growth of nearly 2.3%. Therefore, the rising number of patients diagnosed with cystic fibrosis is driving the growth of the cystic fibrosis (CF) therapeutics market.

Major companies operating in the cystic fibrosis (CF) therapeutics market are advancing treatment and patient care solutions, such as cystic fibrosis innovation hub networks, to speed up research, expand treatment options, and strengthen collaboration in the development of new therapies for CF patients. A cystic fibrosis innovation hub network is a collaborative platform or initiative aimed at accelerating the research and development of novel treatments for cystic fibrosis. For instance, in October 2024, LifeArc, a UK-based charity and life sciences organization focused on translating scientific research into practical healthcare solutions, launched the UK’s first Cystic Fibrosis Innovation Hub Network. The Cystic Fibrosis Innovation Hub Network is designed to support research and development for CF treatments by promoting collaboration among healthcare providers, researchers, and patients. Introduced as part of a broader effort to accelerate innovation in cystic fibrosis therapies, the hub concentrates on identifying new drug development pathways and improving patient outcomes.

In July 2024, Sionna Therapeutics, a US-based healthcare organization, acquired the rights to develop and commercialize multiple cystic fibrosis (CF) compounds from AbbVie Inc. for an undisclosed amount. Through this acquisition, Sionna aims to advance the commercialization of three specific compounds - ABBV-2222, ABBV-3067, and ABBV-2851 - to enhance treatment effectiveness for cystic fibrosis. AbbVie Inc. is a US-based company that offers cystic fibrosis (CF) therapeutics.

Major companies operating in the cystic fibrosis (cf) therapeutics market are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals, Translate Bio Inc, Zambon S.p.A.

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cystic fibrosis (cf) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the cystic fibrosis therapeutics market by increasing the cost of importing specialized drugs, medical devices, and active pharmaceutical ingredients. The impact is most pronounced in segments like CFTR modulators and inhaled therapies, particularly in regions such as Asia-Pacific and Africa. While tariffs have raised production and distribution costs, they have also encouraged local manufacturing initiatives and incentivized regional partnerships, promoting more localized supply chains and fostering innovation in cost-efficient CF treatments.

The cystic fibrosis (cf) therapeutics market research report is one of a series of new reports that provides cystic fibrosis (cf) therapeutics market statistics, including cystic fibrosis (cf) therapeutics industry global market size, regional shares, competitors with a cystic fibrosis (cf) therapeutics market share, detailed cystic fibrosis (cf) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis (cf) therapeutics industry. This cystic fibrosis (cf) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cystic fibrosis (CF) therapeutics refer to medications that help thin lung mucus and make it easier to cough out. Cystic fibrosis is a genetic disorder that leads to serious damage to the lungs, digestive system, and other organs in the body.

The major drug classes used in cystic fibrosis (CF) therapeutics include pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Pancreatic enzyme supplements are products derived from the pancreas and contain pancreatin or pancrelipase, a mixture of lipase, amylase, and protease. These therapies are administered through oral and inhaled routes and encompass various treatment approaches for cystic fibrosis using both medications and medical devices.

The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.